Emergent BioSolutions Inc. (EBS) Stock Score, Valuation & Financial Research
Emergent BioSolutions Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 31/100.
Quick answer for EBS
Emergent BioSolutions Inc. currently has a Wall Street Score of 31/100. The stored market price is $5.87. Its financial score is 17/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Emergent BioSolutions Inc. does
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device
EBS financial snapshot
- Wall Street Score:
- 31/100
- Current price:
- $5.87
- Market capitalization:
- $302.9M
- Revenue:
- $770.2M
- Net income:
- $-176.8M
- Free cash flow:
- $156.8M
- Cash:
- $139.7M
- Total debt:
- $581.8M
- EPS:
- -3.44
- Financial score:
- 17/100
- Valuation score:
- 0/100
- Revenue score:
- 24/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $156.8M, showing positive cash generation.
- The balance sheet shows $139.7M of cash versus $581.8M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 17/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research EBS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.